| Literature DB >> 31666071 |
Lidia García-Pérez1,2,3,4,5, Vanesa Ramos-García6,7, Pedro Serrano-Aguilar7,8,9, José Luis Pais-Brito10,11, María Aciego de Mendoza10, Jesús Martín-Fernández8,12,13, Roberto García-Maroto14, Juan Carlos Arenaza8,15, Amaia Bilbao8,16.
Abstract
BACKGROUND: The objective of this study was to obtain utilities by means of EQ-5D-5L for different health states in patients with knee osteoarthritis (KOA) or hip osteoarthritis (HOA) in Spain, and to compare these values with those used in foreign studies with the aim of discussing their transferability for their use in economic evaluations conducted in Spain.Entities:
Keywords: EQ-5D-5L; Health states; Hip osteoarthritis; Knee osteoarthritis; Utilities
Mesh:
Year: 2019 PMID: 31666071 PMCID: PMC6822337 DOI: 10.1186/s12955-019-1230-x
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Characteristics of the samples with knee and hip osteoarthritis
| Characteristic | Knee osteoarthritis | Hip osteoarthritis | |||||||
|---|---|---|---|---|---|---|---|---|---|
| N | % | Mean | SD | N | % | Mean | SD | ||
| Age (years) | 397 | 71.42 | 9.06 | 361 | 67.88 | 11.67 | |||
| Sex | Women | 277 | 70 | 192 | 53 | ||||
| Men | 120 | 30 | 169 | 47 | |||||
| Region | Basque Country | 158 | 40 | 157 | 44 | ||||
| Canary Islands | 81 | 20 | 80 | 22 | |||||
| Madrid | 158 | 40 | 124 | 34 | |||||
| Type of health center | Primary healthcare center | 230 | 58 | 204 | 57 | ||||
| Hospital | 167 | 42 | 157 | 44 | |||||
| Joint with osteoarthritis | Right | 110 | 28 | 138 | 38 | ||||
| Left | 119 | 30 | 121 | 34 | |||||
| Both joints | 168 | 42 | 102 | 28 | |||||
| BMI | 389 | 29.67 | 4.87 | 355 | 28.16 | 4.57 | |||
| Weight (kg) | 395 | 77.67 | 14.00 | 357 | 76.47 | 15.04 | |||
| Height (cm) | 389 | 161.93 | 8.57 | 356 | 164.57 | 8.84 | |||
| Charlson Index (No of comorbidities) | 395 | 0.78 | 1.14 | 361 | 0.84 | 1.31 | |||
| WOMAC – Pain score (0–100) | 396 | 47.00 | 20.49 | 360 | 45.81 | 22.77 | |||
| WOMAC – Stiffness score (0–100) | 396 | 46.81 | 25.42 | 360 | 48.26 | 26.05 | |||
| WOMAC – Physical function score (0–100) | 397 | 51.08 | 20.95 | 360 | 52.43 | 23.05 | |||
| WOMAC Score (0–100) | 397 | 49.63 | 20.32 | 359 | 50.69 | 22.25 | |||
| Oxford Scale Score (0–48) | 395 | 21.96 | 9.96 | 359 | 22.84 | 10.62 | |||
| EQ-5D-5 L Index | 393 | 0.544 | 0.271 | 357 | 0.520 | 0.304 | |||
| EQ-5D VAS (0–100) | 390 | 57.36 | 21.55 | 359 | 54.47 | 22.27 | |||
BMI Body mass index, SD Standard deviation, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index
WOMAC: 0, worst; 100, best
Oxford Scale Score: 0, worst; 48, best (severity of arthritis)
EQ-5D-5 L Index: 0, death; 1, perfect health
Percentage of patients with knee osteoarthritis reporting levels within EQ-5D-5 L dimensions
| Group | Dimension | Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
|---|---|---|---|---|---|---|
The whole sample ( | Mobility | 11.8 | 16.6 |
| 24.4 | 1.3 |
| Self-care |
| 27.0 |
| 8.8 | 0 | |
| Usual activities | 16.6 | 26.7 |
| 15.9 | 4.3 | |
| Pain/Discomfort | 4.0 | 23.2 |
| 30.2 | 4.0 | |
| Anxiety/Depression |
| 24.2 | 18.1 | 10.8 | 2.5 | |
OKS – severe ( | Mobility | 2.4 | 7.1 | 36.9 |
| 3.0 |
| Self-care | 10.1 | 18.5 |
| 19.6 | 0 | |
| Usual activities | 2.4 | 10.1 |
| 33.9 | 8.9 | |
| Pain/Discomfort | 1.2 | 3.0 | 33.9 |
| 9.5 | |
| Anxiety/Depression |
| 23.2 | 25.6 | 17.9 | 5.4 | |
OKS - moderate to severe ( | Mobility | 5.5 | 17.2 |
| 7.8 | 0 |
| Self-care | 28.1 |
| 27.3 | 1.6 | 0 | |
| Usual activities | 10.9 | 36.7 |
| 4.7 | 1.6 | |
| Pain/Discomfort | 0.8 | 23.4 |
| 24.2 | 0 | |
| Anxiety/Depression |
| 25.8 | 20.3 | 9.4 | 0 | |
OKS - mild to moderate ( | Mobility | 29.7 |
|
| 0 | 0 |
| Self-care |
| 28.4 | 2.7 | 0 | 0 | |
| Usual activities | 39.2 |
| 9.5 | 0 | 0 | |
| Pain/Discomfort | 10.8 |
| 32.4 | 1.4 | 0 | |
| Anxiety/Depression |
| 27.0 | 2.7 | 1.4 | 1.4 | |
OKS - satisfactory joint function ( | Mobility |
| 19.0 | 14.3 | 0 | 0 |
| Self-care |
| 0 | 0 | 0 | 0 | |
| Usual activities |
| 4.8 | 9.5 | 0 | 0 | |
| Pain/Discomfort | 19.0 |
| 14.3 | 0 | 0 | |
| Anxiety/Depression |
| 14.3 | 4.8 | 0 | 0 |
Level 1: indicating no problem; Level 2: indicating slight problems; Level 3: indicating moderate problems; Level 4: indicating severe problems; Level 5: indicating extreme problems
Highest frequencies are highlighted in bold letters
Utility weights (EQ-5D-5 L Index) per subgroup in patients with knee osteoarthritis
| Subgroup | N | Mean | SD | ||
|---|---|---|---|---|---|
| Age groups (years) | < 45 | 1 | 0.746 | ||
| 45–54.99 | 17 | 0.516 | 0.302 | ||
| 55–64.99 | 71 | 0.540 | 0.269 | ||
| 65–74.99 | 143 | 0.564 | 0.279 | ||
| 75–84.99 | 143 | 0.523 | 0.264 | ||
| ≥85 | 18 | 0.589 | 0.258 | ||
| Gender | Women | 275 | 0.528 | 0.269 | 0.079 |
| Men | 118 | 0.581 | 0.274 | ||
| Region | Basque Country | 154 | 0.503 | 0.570 | 0.053 |
| Madrid | 158 | 0.572 | 0.252 | ||
| Canary Islands | 81 | 0.568 | 0.270 | ||
| BMI categories | Underweighta | 0 | – | – | 0.029 |
| Normalb | 61 | 0.590 | 0.214 | ||
| Overweightc | 154 | 0.577 | 0.261 | ||
| Obesityd | 161 | 0.500 | 0.299 | ||
| Morbid obesitye | 10 | 0.465 | 0.215 | ||
| Joint with osteoarthritis | Right knee | 109 | 0.559 | 0.261 | 0.752 |
| Left knee | 117 | 0.546 | 0.259 | ||
| Both knees | 167 | 0.533 | 0.287 | ||
| Time since osteoarthritis diagnosis (years) | <1 | 62 | 0.602 | 0.245 | 0.188 |
| 1 to < 5 | 181 | 0.547 | 0.269 | ||
| 5 to < 10 | 93 | 0.536 | 0.270 | ||
| 10 to < 15 | 35 | 0.466 | 0.307 | ||
| ≥15 | 21 | 0.513 | 0.297 | ||
| Contralateral knee | Without prosthesis in the other knee | 314 | 0.546 | 0.275 | 0.986 |
| With prosthesis in the other knee | 78 | 0.545 | 0.250 | ||
| Other joints | Hip osteoarthritis | 53 | 0.519 | 0.312 | 0.101 |
| No hip osteoarthritis | 339 | 0.549 | 0.265 | ||
| Osteoarthritis in other joints | 228 | 0.535 | 0.273 | 0.813 | |
| No osteoarthritis in other joints | 164 | 0.558 | 0.269 | ||
| Number of comorbidities (Charlson Index) | No comorbidity | 215 | 0.572 | 0.257 | 0.149 |
| 1 comorbidity | 104 | 0.523 | 0.282 | ||
| 2 comorbidities | 40 | 0.504 | 0.301 | ||
| 3 comorbidities | 18 | 0.435 | 0.279 | ||
| ≥4 comorbidities | 14 | 0.522 | 0.282 | ||
| WOMAC | Pain score 0 to <25a | 42 | 0.783bcd | 0.187 | < 0.0001 |
| Pain score 25 to < 50b | 163 | 0.648acd | 0.186 | ||
| Pain score 50 to <75c | 139 | 0.450abd | 0.248 | ||
| Pain score 75 to 100d | 48 | 0.252abc | 0.283 | ||
| Stiffness score 0 to <25a | 44 | 0.716cd | 0.207 | < 0.0001 | |
| Stiffness score 25 to < 50b | 134 | 0.652cd | 0.215 | ||
| Stiffness score 50 to <75c | 127 | 0.506abd | 0.250 | ||
| Stiffness score 75 to 100d | 87 | 0.347abc | 0.277 | ||
| Physical function score 0 to <25a | 41 | 0.845bcd | 0.113 | < 0.0001 | |
| Physical function score 25 to <50b | 146 | 0.664acd | 0.173 | ||
| Physical function score 50 to <75c | 143 | 0.475abd | 0.205 | ||
| Physical function score 75 to 100d | 63 | 0.230abc | 0.293 | ||
| WOMAC Score 0 to <25a | 44 | 0.829bcd | 0.117 | < 0.0001 | |
| WOMAC Score 25 to <50b | 145 | 0.665acd | 0.172 | ||
| WOMAC Score 50 to <75c | 143 | 0.464abd | 0.220 | ||
| WOMAC Score 75 to 100d | 50 | 0.189abc | 0.277 | ||
| Oxford Knee Score (OKS) | Severe (0–19)a | 168 | 0.346bcd | 0.255 | < 0.0001 |
| Moderate to severe (20–29)b | 128 | 0.609acd | 0.157 | ||
| Mild to moderate (30–39)c | 74 | 0.780abd | 0.109 | ||
| Satisfactory joint function (40–48)d | 21 | 0.879abc | 0.097 | ||
| Non-surgery treatments | No pharmacologic treatment | 53 | 0.579 | 0.299 | 0.321 |
| Any pharmacologic treatment | 340 | 0.539 | 0.267 | ||
| Symptomatic slow acting drugs for osteoarthritis (SYSADOA) | 50 | 0.564 | 0.247 | 0.567* | |
| Non-opioid pain medication | 242 | 0.546 | 0.263 | 0.919* | |
| Nonsteroidal anti-inflammatory drugs (NSAID) | 152 | 0.529 | 0.283 | 0.529* | |
| Opiate derivatives | 96 | 0.538 | 0.274 | 0.836* | |
| Opioid pain medication | 21 | 0.333 | 0.309 | 0.005* | |
| Rehabilitation / Physiotherapy | 14 | 0.559 | 0.295 | 0.854* | |
| Knee replacement | Waiting for prosthesis | 92 | 0.400 | 0.266 | < 0.0001** |
| Prosthesis in the last 6 months | 65 | 0.683 | 0.243 | ||
| Complication after prosthesis | 2 | 0.424 | 0.007 | – | |
BMI Body mass index, SD Standard deviation, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index
p-values represents the significance of differences between groups by means of ANOVA except for (*) P-value comparing with the whole sample’s utility value (0.544) (one sample t-test), and (**) P-value comparing sample before and after (6 months) the prosthesis (paired sample t-test)
Superscript letters indicate differences among the subgroups according to Tamhane’s T2 post hoc test for multiple comparisons at P-value< 0.01
Percentage of patients with hip osteoarthritis reporting levels within EQ-5D-5 L dimensions
| Group | Dimension | Level 1 | Level 2 | Level 3 | Level 4 | Level 5 |
|---|---|---|---|---|---|---|
The whole sample ( | Mobility | 10.5 | 23.8 |
| 23.3 | 2.8 |
| Self-care | 25.2 | 27.7 |
| 13.6 | 1.9 | |
| Usual activities | 16.6 | 23.0 |
| 17.2 | 5.8 | |
| Pain/Discomfort | 8.3 | 20.2 |
| 30.2 | 6.1 | |
| Anxiety/Depression |
| 23.2 | 18.0 | 10.8 | 3.9 | |
OHS – severe ( | Mobility | 0.7 | 3.4 | 38.9 |
| 6.7 |
| Self-care | 4.0 | 12.8 |
| 30.2 | 4.0 | |
| Usual activities | 2.0 | 5.4 |
| 36.9 | 12.1 | |
| Pain/Discomfort | 0 | 4.0 | 24.2 |
| 13.4 | |
| Anxiety/Depression | 21.5 | 19.5 |
| 18.8 | 8.7 | |
OHS - moderate to severe ( | Mobility | 3.4 | 32.8 |
| 6.9 | 0 |
| Self-care | 20.7 |
| 32.8 | 2.6 | 0 | |
| Usual activities | 8.6 | 36.2 |
| 6.0 | 1.7 | |
| Pain/Discomfort | 1.7 | 21.6 |
| 18.1 | 0.9 | |
| Anxiety/Depression |
| 35.3 | 11.2 | 9.5 | 0.9 | |
OHS - mild to moderate ( | Mobility | 26.2 |
| 23.0 | 0 | 0 |
| Self-care |
| 39.3 | 3.3 | 1.6 | 0 | |
| Usual activities | 39.3 |
| 18.0 | 0 | 0 | |
| Pain/Discomfort | 16.4 |
| 29.5 | 1.6 | 0 | |
| Anxiety/Depression |
| 18.0 | 8.2 | 0 | 0 | |
OHS - satisfactory joint function ( | Mobility |
| 27.6 | 13.8 | 0 | 0 |
| Self-care |
| 13.8 | 0 | 0 | 0 | |
| Usual activities |
| 20.7 | 6.9 | 0 | 0 | |
| Pain/Discomfort |
| 31.0 | 10.3 | 0 | 0 | |
| Anxiety/Depression |
| 6.9 | 0 | 0 | 0 |
Level 1: indicating no problem; Level 2: indicating slight problems; Level 3: indicating moderate problems; Level 4: indicating severe problems; Level 5: indicating extreme problems
Highest frequencies are highlighted in bold letters
Utility weights (EQ-5D-5 L Index) per subgroup in patients with hip osteoarthritis
| Subgroup | N | Mean | SD | ||
|---|---|---|---|---|---|
| Age groups (years) | < 45 | 13 | 0.591 | 0.357 | 0.259 |
| 45–54.99 | 37 | 0.506 | 0.291 | ||
| 55–64.99 | 83 | 0.465 | 0.291 | ||
| 65–74.99 | 101 | 0.507 | 0.298 | ||
| 75–84.99 | 103 | 0.562 | 0.299 | ||
| ≥85 | 20 | 0.584 | 0.380 | ||
| Gender | Women | 188 | 0.512 | 0.305 | 0.606 |
| Men | 169 | 0.529 | 0.304 | ||
| Region | Basque Countrya | 154 | 0.473 | 0.313 | 0.036 |
| Madridb | 124 | 0.553 | 0.288 | ||
| Canary Islandsc | 79 | 0.562 | 0.301 | ||
| BMI categories | Underweight | 2 | 0.339 | 0.572 | 0.372 |
| Normal | 87 | 0.552 | 0.305 | ||
| Overweight | 154 | 0.530 | 0.288 | ||
| Obesity | 102 | 0.473 | 0.324 | ||
| Morbid obesity | 5 | 0.541 | 0.241 | ||
| Joint with osteoarthritis | Right hip | 135 | 0.481 | 0.320 | 0.059 |
| Left hip | 121 | 0.571 | 0.285 | ||
| Both hip | 101 | 0.511 | 0.297 | ||
| Time since osteoarthritis diagnosis (years) | <1 | 118 | 0.541 | 0.279 | 0.240 |
| 1 to <5 | 152 | 0.492 | 0.309 | ||
| 5 to < 10 | 63 | 0.520 | 0.347 | ||
| 10 to < 15 | 14 | 0.675 | 0.204 | ||
| ≥15 | 8 | 0.523 | 0.288 | ||
| Contralateral hip | Without prosthesis in the other hip | 293 | 0.510 | 0.303 | 0.182 |
| With prosthesis in the other hip | 62 | 0.567 | 0.302 | ||
| Other joints | Knee osteoarthritis | 115 | 0.522 | 0.322 | 0.303 |
| No knee osteoarthritis | 241 | 0.521 | 0.295 | ||
| Osteoarthritis in other joints | 214 | 0.537 | 0.301 | 0.801 | |
| No osteoarthritis in other joints | 142 | 0.499 | 0.306 | ||
| Number of comorbidities (Charlson Index) | No comorbiditya | 206 | 0.561 | 0.284 | 0.033 |
| 1 comorbidityb | 71 | 0.465 | 0.323 | ||
| 2 comorbiditiesc | 46 | 0.495 | 0.334 | ||
| 3 comorbiditiesd | 18 | 0.386 | 0.370 | ||
| ≥4 comorbiditiese | 16 | 0.460 | 0.210 | ||
| WOMAC | Pain score 0 to <25a | 54 | 0.818bcd | 0.146 | < 0.0001 |
| Pain score 25 to <50b | 143 | 0.643acd | 0.175 | ||
| Pain score 50 to <75c | 110 | 0.414abd | 0.243 | ||
| Pain score 75 to 100d | 49 | 0.074abc | 0.250 | ||
| Stiffness score 0 to <25a | 42 | 0.795bcd | 0.181 | < 0.0001 | |
| Stiffness score 25 to <50b | 107 | 0.656acd | 0.220 | ||
| Stiffness score 50 to <75c | 118 | 0.509abd | 0.241 | ||
| Stiffness score 75 to 100d | 89 | 0.243abc | 0.294 | ||
| Physical function score 0 to <25a | 48 | 0.878bcd | 0.098 | < 0.0001 | |
| Physical function score 25 to <50b | 115 | 0.672acd | 0.144 | ||
| Physical function score 50 to <75c | 125 | 0.464abd | 0.225 | ||
| Physical function score 75 to 100d | 69 | 0.120abc | 0.229 | ||
| WOMAC Score 0 to <25a | 47 | 0.864bcd | 0.122 | < 0.0001 | |
| WOMAC Score 25 to <50b | 124 | 0.673acd | 0.145 | ||
| WOMAC Score 50 to <75c | 120 | 0.429abd | 0.232 | ||
| WOMAC Score 75 to 100d | 56 | 0.081abc | 0.222 | ||
| Oxford Hip Score (OHS) | Severe (0–19)a | 149 | 0.269bcd | 0.264 | < 0.0001 |
| Moderate to severe (20–29)b | 116 | 0.611acd | 0.146 | ||
| Mild to moderate (30–39)c | 61 | 0.783abd | 0.101 | ||
| Satisfactory joint function (40–48)d | 29 | 0.903abc | 0.102 | ||
| Non-surgery treatments | No pharmacologic treatment | 69 | 0.544 | 0.312 | 0.491 |
| Any pharmacologic treatment | 287 | 0.516 | 0.301 | ||
| Symptomatic slow acting drugs for osteoarthritis (SYSADOA) | 34 | 0.574 | 0.320 | 0.331* | |
| Non-opioid pain medication | 197 | 0.503 | 0.309 | 0.435* | |
| Nonsteroidal anti-inflammatory drugs (NSAID) | 128 | 0.533 | 0.304 | 0.613* | |
| Opiate derivatives | 97 | 0.498 | 0.304 | 0.474* | |
| Opioid pain medication | 13 | 0.435 | 0.378 | 0.434* | |
| Rehabilitation / Physiotherapy | 10 | 0.598 | 0.227 | 0.305* | |
| Hip replacement | Waiting for prosthesis | 97 | 0.379 | 0.313 | < 0.0001** |
| Prosthesis in the last 6 months | 65 | 0.730 | 0.208 | ||
| Complication after prosthesis | 5 | 0.556 | 0.432 | – | |
BMI Body mass index; SD Standard deviation; WOMAC Western Ontario and McMaster Universities Osteoarthritis Index
P-values represents the significance of differences between groups by means of ANOVA except for (*) P-value comparing with the whole sample’s utility value (0.520) (one sample t-test), and (**) P-value comparing sample before and after (6 months) the prosthesis (paired sample t-test)
Superscript letters indicate differences among the subgroups according to Bonferroni (region and number of comorbidities) or Tamhane’s T2 (WOMAC, OHS) post hoc tests for multiple comparisons at P-value< 0.01